Literature DB >> 15875183

Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.

Ramón Bosch Príncep1, Marylène Lejeune, Maria Teresa Salvadó Usach, Joaquín Jaén Martínez, Lluis E Pons Ferré, Tomás Alvaro Naranjo.   

Abstract

This study aimed to assess the differences in the cellular composition of the inflammatory reactive background around tumoral cells of classical Hodgkin's lymphomas (cHL) inside and outside the HIV settings. This retrospective study evaluates the infiltrating T lymphocytes (CD4 and CD8), natural killer cells (CD57+ cells), and more especially cytotoxic cells [granzyme B (GrB) and TIA-1+ cells] in the background of 99 EBV+ cHL. Sections from paraffin-embedded tumor samples from nine HIV-infected cHL patients were immunostained, using standard immunohistochemical protocols and were compared to a control group of 90 HIV-noninfected cHL patients. Our clinical and histological data indicate that HIV-infected cHL patients present a higher frequency of mixed cellularity (MC) histological subtypes, more advanced disease stages, a poor response to treatment, and a poor overall survival compared to control patients. In controls, CD4/CD8 and GrB/TIA-1 ratios were determined as 2:1 and 1:2, respectively. The inflammatory infiltrate of HIV-infected patients had a significant reduction of CD4+ T lymphocytes (CD4/CD8 ratio 1:23), a decrease in infiltrating GrB+ cells (activated cytotoxic cells) and an increase in infiltrating TIA+ T cells (mainly nonactivated cytotoxic cells) in these patients (GrB/TIA-1 ratio 1:12). In conclusion, this study highlights an important intratumoral loss of CD4+ T cells (striking inversion in the CD4/CD8 ratio) and a decrease in intratumoral activated cytotoxic T lymphocytes in HIV-associated cHL patients. Further studies are required to confirm these results and to determine the role of these findings on the antitumoral immune response observed in HIV-associated cHL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875183     DOI: 10.1007/s00277-005-1051-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  11 in total

1.  Automated quantification of nuclear immunohistochemical markers with different complexity.

Authors:  Carlos López; Marylène Lejeune; María Teresa Salvadó; Patricia Escrivà; Ramón Bosch; Lluis E Pons; Tomás Alvaro; Jordi Roig; Xavier Cugat; Jordi Baucells; Joaquín Jaén
Journal:  Histochem Cell Biol       Date:  2008-01-03       Impact factor: 4.304

2.  Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure.

Authors:  Marylène Lejeune; Joaquín Jaén; Lluis Pons; Carlos López; Maria-Teresa Salvadó; Ramón Bosch; Marcial García; Patricia Escrivà; Jordi Baucells; Xavier Cugat; Tomás Alvaro
Journal:  J Anat       Date:  2008-06       Impact factor: 2.610

Review 3.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

Review 4.  [Lymph node pathology - an update].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

5.  High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088).

Authors:  Adriana Weinberg; Petronella Muresan; Terence Fenton; Kelly Richardson; Teresa Dominguez; Anthony Bloom; Elizabeth Petzold; Patricia Anthony; Coleen K Cunningham; Stephen A Spector; Sharon Nachman; George K Siberry; Edward Handelsman; Patricia M Flynn
Journal:  Hum Vaccin Immunother       Date:  2013-01-31       Impact factor: 3.452

Review 6.  Update on HIV lymphoma.

Authors:  Ariela Noy
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 7.  Hodgkin lymphoma: an update on its biology with new insights into classification.

Authors:  Haresh Mani; Elaine S Jaffe
Journal:  Clin Lymphoma Myeloma       Date:  2009-06

Review 8.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

Review 9.  Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.

Authors:  Tomás Alvaro; Luis de la Cruz-Merino; Fernando Henao-Carrasco; José Luis Villar Rodríguez; David Vicente Baz; Manuel Codes Manuel de Villena; Mariano Provencio
Journal:  J Biomed Biotechnol       Date:  2010-08-12

10.  CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.

Authors:  Katherine Antel; D Chetty; J Oosthuizen; Z Mohamed; L Van der Vyver; E Verburgh
Journal:  Pathology       Date:  2021-02-06       Impact factor: 5.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.